GlassScriptPhysician profile
Frederico Padin
NPI 1598747198
$5,209.00
in general payments reported to CMS, 2019-2025
23 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $879 · 2021: $1,324 · 2022: $1,095 · 2023: $577 · 2024: $433 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,853.23 | 2019-2024 | Veozah, Myrbetriq |
| Janssen Biotech, INC. | $925.96 | 2019-2024 | Erleada, Rybrevant, Akeega |
| Sumitomo Pharma America, INC. | $457.58 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $435.76 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $239.33 | 2020-2022 | |
| Teleflex LLC | $233.07 | 2021-2024 | Urolift |
| Urovant Sciences INC | $209.50 | 2021-2022 | |
| Neotract INC. | $159.88 | 2020 | |
| Antares Pharma, INC. | $138.53 | 2019-2025 | Xyosted |
| Myovant Sciences INC. | $117.51 | 2021-2022 | |
| Daiichi Sankyo INC. | $115.68 | 2022 | |
| Ferring Pharmaceuticals INC. | $55.82 | 2019 | |
| Verity Pharmaceuticals INC. | $40.76 | 2024-2025 | Tlando |
| Aytu Biopharma, INC. | $32.10 | 2019 | |
| Myriad Genetic Laboratories, INC. | $27.56 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $24.88 | 2025 | |
| Tolmar, INC. | $23.30 | 2025 | Eligard, Jatenzo |
| Merck Sharp & Dohme LLC | $22.54 | 2022 | |
| Boston Scientific Corporation | $20.05 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $19.67 | 2021 | |
| Ambu INC. | $19.03 | 2022 | |
| Novo Nordisk INC | $18.84 | 2025 | Wegovy |
| Olympus America INC. | $18.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederico Padin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.